Tyler Shropshire: Negative Prognostic Effect OF TI-CH on Patient Survival
Tyler Shropshire Vice President, Global Biopharma Business Development, Head of Real World Data at Caris Life Sciences, shared a post on LinkedIn:
“Caris Life Sciences recently published an independent validation of the intriguing results of Oriol Pich Roselló et al. in the New England Journal of Medicine.
In this study involving RWD from over 3,000 matched blood and tissue NGS samples from late-stage patients, we demonstrate that tumor-infiltrating clonal hematopoiesis (“TI-CH”) has a negative prognostic effect on patient survival.
Why should we care?
The combined findings suggest that without concurrent tumor/clonal hematopoiesis sequencing, we could be detecting mutations that do not come from the tumor. This could then lead to the application of a (toxic) therapy that targets a tumor mutation that simply does not exist.
Congratulations to all of the authors on the original paper and validation – making precision medicine more precise.”
Prevalence and Clinical Significance of Blood-Only CHIP and TI-CH in Patients with Solid Tumors.
More posts on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023